Skip to content

Clinical Study for Huazhuo Tongmai Decoction in the Treatment of Primary Hyperlipidemia Complicated with Carotid Atherosclerosis

Clinical Study for Huazhuo Tongmai Decoction in the Treatment of Primary Hyperlipidemia Complicated with Carotid Atherosclerosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025282
Enrollment
Unknown
Registered
2019-08-21
Start date
2016-05-31
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hyperlipidemia with carotid atherosclerosis

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Accord with the diagnostic criteria of hyperlipidemia: accord with any of the following: TC (> 6.22 mmol/L); 2.26 mmol/L (= TG (= 5.63 mmol/L); 2) LDL-C (> 4.14 mmol/L); 3) Accord with the diagnostic criteria of carotid atherosclerosis; 4) TCM syndrome differentiation belongs to phlegm stagnation syndrome; 5) Aged between 30 and 70 years; 6) The research program is approved and signed by the ethical committees of clinical research. The patient knows and voluntarily signs the informed consent; 7) Those who have stopped taking lipid-lowering drugs for more than 4 weeks or met the above criteria at the end of the introduction period.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women, allergic constitution and drug allergy; 2) Patients who have suffered from acute myocardial infarction, cerebrovascular accident, severe trauma or major surgery within six months; 3) Secondary hyperlipidemia; 4) Hyperlipidemia and homozygous hypercholesterolemia caused by drugs (phenothiazines, beta-blockers adrenocorticosteroids and some contraceptives, etc.); 5) Patients who are using heparin, thyroxine or other drugs that affect lipid metabolism, and those who have taken other lipid-lowering measures in the past two weeks; 6) Psychiatric patients with severe primary diseases such as liver, kidney and hematopoietic system.

Design outcomes

Primary

MeasureTime frame
LDL-C;TC;TG;

Secondary

MeasureTime frame
HDL-C;Crouse;Integral of TCM Syndrome;

Countries

China

Contacts

Public ContactTong Wenxin

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

xiyuanky@263.net+86 010-62835398

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026